Kevin Hern: “One way to do this is by reducing the regulatory burden so that Title IV-B funding recipients can spend more time…”

I will always advocate for those who are suffering from a rare disease and support efforts to bring treatments for these diseases to market.

I think it is important for everyone to know--and you know this to be certain--corporations don't pay taxes.

How harmful would it be for not only our economy, but our democracy, if Congress's hands were ever forced to rubber stamp Biden's poorly negotiated global minimum tax?

It’s what the president got elected on.